Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib
Phase 4
Completed
NCT00756509
| Condition | Gastrointestinal Stromal Tumors |
|---|
| Phase | Phase 4 |
|---|
| Sponsor | Novartis Pharmaceuticals |
|---|
| Status | Completed |
|---|
| Enrollment | 34 participants |
|---|
| Interventions | Nilotinib |
|---|
| Start date | Aug 29, 2008 |
|---|
| Completion date | Dec 18, 2024 |
|---|
| Results posted | Jan 20, 2026 |
|---|
Summary
The purpose of this multicenter, single-arm, phase II trial is to evaluate the efficacy of Nilotinib in patients with unresectable or metastatic gastrointestinal stromal tumors (GIST).
Proportion of Participants With Best Overall Response at Month 6 (Core Phase) Determined According to the RECIST v1.0.
from baseline to month 6, core phase · Participants
| Nilotinib | 0 Participants |
|---|
| Nilotinib | 14 Participants |
|---|
| Nilotinib | 21 Participants |
|---|
| Nilotinib | 6 Participants |
|---|
| Nilotinib | 0 Participants |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.